Introduction
Interleukin-10 (IL-10), produced by macrophages and Th2 cells, was originally described as a cytokine synthesis inhibitory factor. It is able to negatively regulate a variety of immune responses and inhibits the synthesis of Th1 cell cytokines, particularly interferon-g (IFN-g).
1-6 IL-10 strongly downregulates class II major histocompatibility complex (MHC) expression on monocytes 5 and blocks accessory cell function of macrophages by decreasing expression of the costimulatory molecule B7. 7 However, IL-10 also has immunostimulatory properties, especially on B cells and activated CD 8 + T cells. [8] [9] [10] Viral IL-10 (vIL-10), a gene product encoded by the Epstein-Barr virus (EBV) BamH1 C-fragment rightwards reading frame (BCRF), is a biologically active homologue of human IL-10 that plays a pivotal role in immune evasion and viral persistence. Viruses lacking this gene may compensate by inducing the production of cellular IL-10 in host cells. [11] [12] [13] [14] vIL-10 shares many biological properties with human IL-10, including inhibition of cytokine synthesis and downregulation of class II MHC expression in monocytes. 2 However, vIL-10 does not possess the T-cell costimulatory activities of authentic cellular IL-10, 2, 15 which may make vIL-10 the more potent immunosuppressant and a promising candidate cytokine for therapeutic use in organ transplantation. A number of clinical studies have confirmed that increased IL-10 expression is associated with poor or absent immune response against infectious pathogens 16 and that elevated IL-10 levels correlate with prolonged graft survival. 17 Since 1996, a number of groups have used gene therapy to deliver vIL-10 into cardiac allografts in experimental animals using various nonviral plasmid vectors 18 or viral vectors, such as retroviral 19 and adenoviral vectors. [20] [21] [22] Soluble vIL-10 secreted within the transplanted organ is likely to exert a local in vivo effect at the interface between the immune system and alloantigens, without requiring expression in all target cells. So far, however, expression of vIL-10 within donor cardiac allografts has not led to permanent graft acceptance and prolongation of graft survival has been modest. It is therefore unclear how clinically useful this strategy will be. The limited survival benefit observed was suggested to be due to transient gene expression and/or insufficient levels of vIL-10 expression. 23 Alternative vectors, which can achieve more effective and sustained gene expression, are needed if vIL-10 is to be clinically useful.
Vectors based on lentiviruses such as human immunodeficiency virus (HIV) type-1 are emerging as the vectors of choice for in vitro and in vivo gene therapy for a number of conditions. We and others demonstrated HIV-1-based vector gene delivery in the early 1990s following our original identification of the HIV-1 encapsidation signal. 24 Lentiviral vectors have many advantages for gene therapy, including the ability to infect nondividing cells, long-term transgene expression and the absence of induction of an inflammatory/immune response. Lentiviral vectors are pseudotyped with vesicular stomatitis virus (VSV-G) envelope and thus have a broad target cell range. Lentiviral vectors also have a relatively large gene capacity of up to 8 kb.
Previously, we demonstrated that lentiviral vectors could successfully transfer and express exogenous genes (the reporter genes LacZ and GFP) in rat cardiac transplants. 25 In this study, we have investigated whether extended transgene expression of vIL-10, obtainable with lentiviral vectors, could enhance rat cardiac allograft survival. We have also determined potential mechanisms of the vIL-10 effect on T-cell responses to alloantigens in the mixed lymphocyte reaction (MLR) employing bioactive vIL-10 produced by vIL-10-transduced rat aortic endothelial cells (RAECs).
Results

Expression of vIL-10 in cardiac grafts
A series of experiments was undertaken to evaluate the therapeutic approach of lentiviral gene transfer of vIL-10 for promoting allograft survival in a rat model of vascularized heart transplantation.
To determine whether lentiviral transduction was limited to the injected heart tissue or whether it became widespread, RT-PCR analysis of vIL-10 gene expression was performed on Lewis recipients of syngeneic cardiac transplants that were injected with HIV-PGK-vIL-10 (PGK: phosphoglycerate kinase).
Syngeneic cardiac grafts and other recipient tissues were taken on day 28 after heart transplantation. vIL-10 transcripts were only detected in cardiac tissue while all other tissues were free of transgene expression (Figure 1) . No vIL-10 products were detected when the RNA samples were analysed by PCR without the RT step (data not shown). Blood was taken weekly to measure serum vIL-10 but the level of vIL-10 was always below the limit of sensitivity (15 pg/ml), indicating that vIL-10 expression remained highly localized to the cardiac graft.
Lentiviral vector vIL-10 gene transfer prolongs allograft survival
DA rat recipients of fully allogeneic Lewis cardiac grafts injected with HIV-PGK-vIL-10 at 1 Â 10 6 transducing units (TU) at the time of transplantation showed significant prolongation of graft survival from 7.5 days (median graft survival time (MST) for untreated recipients) to 14.5 days (MST, Po0.001; Table 1 ). This dose of HIV-1 vector was not toxic nor did it cause cytopathic effects in the graft, as evidenced by the absence of pathology in syngeneic grafts treated with the same dose. The results are comparable to those reported previously using adenoviral vectors at 1 Â 10 11 TU in a similar cardiac transplant model. 22 Although our syngeneic study showed that the vIL-10 transcript could be clearly detected at day 28, heart grafts in allogeneic recipients were rejected before day 28, suggesting that extended gene expression alone was not sufficient to prolong allograft survival as long as might have been expected. The effect of a single dose of cyclosporin A (CsA) given by gavage at operation at a dose of 10 mg/ kg was investigated. This did not materially alter the results from the vIL-10 vector alone-treated animals ( Table 1) .
Conventional light microscopic examination of allografts 5 days after transplantation showed a similar degree of leucocyte infiltration in grafts injected with saline or empty vector HIV-PGK-f and in those treated with HIV-PKG-vIL-10. Progressive leucocyte infiltration and tissue damage is visible by day 14 and was similar in both treated and mock grafts. Histopathology of the day D o n o r h e a r t B r a i n L u n g L i v e r S p l e e n K i d n e y T e s t i c l e N a t i v e h e a r t vIL-10 GAPDH Figure 1 Detection of vIL-10 mRNA expression in syngeneic cardiac transplants and other tissues. Total RNA was prepared from transduced syngeneic Lewis heart grafts and from recipient native tissues 28 days after transplantation and analysed by RT-PCR using vIL-10-specific primers. Amplified cDNA products were run on 1% agarose gels and stained with ethidium bromide. 20 and has been observed with other forms of immunosuppression; prolongation of heart allograft survival, and even permanent acceptance, is not always associated with decreased leucocyte infiltration. 26, 27 To analyse in more detail the effect of vIL-10 in the allografts and to seek explanations for the limitation of prolongation of allograft survival to around 2 weeks, the kinetics of vIL-10 in vitro and its effect on a primary alloimmune response were investigated. For this study, vIL-10 in the form of transduced cell culture supernatant was used.
Expression of vIL-10 in primary rat neonatal cardiomyocytes and RAECs Figure 3a shows the time course of vIL-10 production in HIV-PGK-vIL-10-transduced RAECs. vIL-10 production rises to a plateau at day 4 post-transduction with a maximum of 60 000 pg/ml. Figure 3b shows the time course of vIL-10 levels in neonatal cardiomyocytes where the peak vIL-10 concentration occurs on day 5 posttransduction. This is significantly delayed compared to adenovirus transduction in which transgene levels reach 70% of peak expression at day 2 in transduced neonatal cardiomyocytes and reach a plateau at day 3 (data not shown). These in vitro data are in agreement with our in vivo data, using HIV-PGK-b-gal vector, 25 that transgenes can be readily detected after day 5 with peak expression at day 7.
vIL-10 inhibits alloantigen-specific T-cell proliferation T cells play a central role in allograft rejection; the effect of vIL-10 on alloantigen-specific T-cell proliferation was investigated using the supernatant harvested from RAECs transduced with HIV-PGK-vIL-10 or HIV-PGK-GFP to use in T-cell proliferation assays. Supernatants from transduced RAEC cultures were collected and stored at À701C and vIL-10 concentration was measured by ELISA before adding to the MLRs; concentrations of 20-25 ng/ml were consistently achieved.
The influence of vIL-10, added at different time points to DA lymphocytes proliferating in response to encounter with alloantigen expressed on irradiated Lewis Figure 4 shows a marked reduction of proliferation when vIL-10 was present at days 1-3. vIL-10 inhibited T-cell proliferation by more than 80% when present on day 1, 2 or 3 of the MLR. The inhibitory effect decreased when addition of vIL-10 to MLRs was delayed until day 4 or 5 (48 and 35% respectively; Figure 4 ). This effect was not due to nonspecific effects of protein or the virus vector preparation since when the supernatant from RAECs transduced with HIV-PGK-GFP was added to MLRs, no inhibitory effect was observed. A similar inhibitory effect of vIL-10 on Con A-stimulated lymphocyte proliferation was also demonstrated (data not shown). Taken together, these results indicate that maximum inhibition of T-cell activation requires early expression of vIL-10 and that vIL-10 did not have the ability to reverse the phenotype of previously activated T cells.
The strong inhibitory effect of vIL-10 was observed at vIL-10 concentrations as low as 0.25 pg/ml for alloantigen-induced proliferation and 2.5 pg/ml for Con A-stimulated lymphocyte proliferation ( Figure 5 ). This suggests that even low levels of vIL-10 have profound effects on lymphocyte proliferation as long as it is present in the early phase of T-cell proliferation.
Discussion
Lentiviral vectors offer major advantages over other vectors due to their ability to transduce nondividing cells, achieve long-term transgene expression and due to the absence of induction by the vector of an inflammatory/immune response. We have shown previously that lentiviral vectors can transduce a cardiac graft. 25 Although only 5% of cardiac myocytes were transduced in vivo, it may be sufficient to modify pathological processes locally, particularly in situations such as heart transplantation where transduction may elicit a secreted effector molecule that can influence bystander and infiltrating cells. 28 In this study, we have addressed the question of whether prolonged vIL-10 gene expression in a cardiac allograft could extend graft survival. vIL-10 possesses immune inhibitory properties that make it a highly promising candidate for use in organ transplantation. Theoretically, augmenting the production of immunosuppressive vIL-10 in the allograft could impair effective antigen presentation, reduce or eliminate immunogenicity, prevent rejection and influence leucocyte infiltration and the balance of cytokines while avoiding the systemic toxicity of conventional immunosuppression. vIL-10 has been delivered to cardiac allografts previously by a variety of plasmids 18 and viral vectors. [19] [20] [21] [22] Its effect on graft survival has been modest and this has been assumed to be due to lack of efficient and sustained gene expression. Nonviral gene vectors generally give low transduction efficiency and oncoretroviral vectors require target cell replication. Adenoviral vectors are efficient for in vivo delivery of genes to a wide variety of tissue types and do not require target cell replication. The major disadvantage of adenoviral vectors is that the duration of expression is limited by the potent adenovirus-specific immune response directed at the infected cell 23 and the fact that vIL-10 expression is systemic and not restricted to the transplanted tissue. Our results showed that lentiviral vectors can generate sustained gene expression for at least 28 days in a syngeneic cardiac graft. Local delivery of vIL-10 into the allograft using lentiviral vectors prolongs allograft survival, but only to a comparable extent to that achieved by adenoviral vectors. Thus, sustained vIL-10 gene expression does not correspond to extended graft survival. It is possible that inflammatory milieu associated with allotransplantaion adversely influenced vIL-10 secretion by the vector-transduced cells. Until this is confirmed, these findings challenge the perception that the limited effect on graft survival of vIL-10 using adenoviral vectors was mainly due to transient gene expression.
It is unlikely that the relatively modest prolongation of graft survival achieved has been limited by production of anti-IL-10 antibodies. Our previous work showed that peak gene expression in the graft occurred at day 7. Rejection occurred at around day 14. Published work using adenoviral vectors showed that an anti-IL-10 response was not detectable even 10 days postexpression 23 and suggested that the generation of an anticytokine response would itself be inhibited by vIL-10.
Studies were conducted to address the kinetics of vIL-10 in promotion of allograft survival. In this study, MLRs were set up in the presence of vIL-10 produced by transduced RAECs. The effect of bioactive secreted vIL-10 on in vitro T-cell responses to alloantigen has previously been studied in vIL-10 gene-transduced dendritic cells 29 and demonstrated a suppressive effect. To supplement our in vivo data, we wished to observe the effect of vIL-10 secreted from cells that are not professional antigen-presenting cells (APC). The in vitro data indicate that vIL-10 has strong immune inhibitory effects on T-cell proliferation and the timing of vIL-10 addition to alloactivated T cells is crucial in its effect. This finding is supported by Li et al, 30 who showed that outcome of vIL-10 administration depends on timing of delivery. The mechanism whereby vIL-10 inhibits T-cell proliferation could be attributed to downregulation of the activation status of APC or to either direct or indirect inhibition of T-cell function. To address this question, further studies are needed to include either preincubating APC with vIL-10 or preincubating T cells with vIL-10, before MLR challenge. vIL-10 may induce regulatory T cells to mediate tolerance 31 but, in this study and using flow cytometry, we were unable to detect CD4+CD25+ regulatory T cells in the in vitro coculture system (data not shown). What is clear from our data is that it is the timing of the vIL-10 intervention that is much more important than the dose.
CsA was used to attempt to suppress the early activation of T cells. This strategy has proven to be effective in adenoviral vector experiments, 20 but in the present study a single (and hence subtherapeutic) (10 mg/kg) dose of CsA administered (by gavage) at the time of transplantation failed to act synergistically with vIL-10 to further enhance allograft survival ( Table  1) . The difference in outcome between lentivirus transduction and adenovirus transduction may be ascribed to different kinetics of peak gene expression. Wang et al 32 reported that direct injection of adenoviruses into the graft gave maximum target gene expression between days 3 and 7 after gene transfer, and much earlier than seen with lentiviral vectors. The delayed peak expression observed on day 7 in our study is probably due to the extended time required for reverse transcription and integration of the vector in lentivirus-based studies. CsA at 10 mg/kg provides sufficient immunosuppression during the first 2 days following transplantation to protect the heart graft until adenovirus transduction delivers effective levels of vIL-10. 22, 33 For lentiviral vector transduction, however, a prolonged CsA treatment regimen will be required during the initial period of T-cell activation until vIL-10 levels become effective. In support of our hypothesis, Qin et al 19 showed that retroviral vectors encoding vIL-10 prolong graft survival significantly longer (graft survival to 39.4+2.5 days) than when using adenoviral vector (graft survival to 18.471.2 days). 23 However, this work was performed in a nonvascularized, murine heart transplant model in which T cells likely have delayed activation compared to fully vascularized heart transplants. It is probable that the synergistic effect of a subtherapeutic dose of CsA together with adenovirus-encoded vIL-10 is not entirely due to CsA-mediated inhibition of an adenovirusspecific immune response as reported by others, 21 but instead a result of early suppression of T-cell activation in response to the vascularized allograft. Inhibition of the host response to adenovirus in order to prolong transgene expression requires a much more vigorous CsA treatment regimen. 34 We have previously shown that cardiac allograft rejection in this rat strain combination is characterized by a range of contributory effector mechanisms including leucocyte infiltration, alloantibody production and Th1 and Th2 cytokine production. At early time points up to day 7 following transplantation, differences in these parameters between rejecting and tolerized heart allografts were not discernible. 35 In the present study, there was no apparent difference in the degree, distribution or phenotype of leucocyte infiltration in the vIL-10-treated or untreated cardiac allografts at days 5 and 14 but it remains possible that analysis of other parameters associated with allograft rejection may have revealed differences that could be attributed to vIL-10, even in the absence of prolonged allograft survival since vIL-10 has been shown to affect multiple pathways of innate and adaptive immunity, which can be activated during allograft rejection. 36 In conclusion, this study demonstrates that constitutively secreted vIL-10 suppression of the recognition phase of the alloimmune response and extended vIL-10 gene expression by lentiviral transduction is likely to be associated with prolongation of allograft survival only if T cells are not fully activated. The early production of vIL-10 is required for adequate suppression of the alloantigenic immune response. The effect of alternative immunosuppressive regimens combined with a lentiviral vector encoding vIL-10 is currently under study.
Materials and methods
Plasmid constructs
A four-plasmid expression system was used to generate third-generation lentiviral vectors by transient transfection as previously described. 37 The vector comprised sequentially from 5 0 to 3 0 : 5 0 LTR, packaging signal sequence, RRE, PGK promoter, reporter gene, WPRE and deleted/mutated 3 0 LTR. No cPPT sequence was included. The four plasmids were (i) the vector plasmid (HIV-PGK-vIL-10) in which the viral promoter had been inactivated, and virtually all the viral accessory proteins had been deleted in order to give the maximum safety. A similar HIV-1 vector without a transgene (HIV-PGK-f) was used as control; (ii) the packaging plasmid provided the HIV structural proteins, Gag and Pol, needed for viral particle production; (iii) the Rev expressor, to provide the Rev protein, which is responsible for efficient vector packaging and expression of RNA; and (iv) the envelope plasmid, VSV-G, for pseudotyping the virion. The vector plasmid, HIV-PGK-vIL-10, contains vIL-10 driven by mouse PGK promoter. The mouse PGK promoter was chosen since we have shown that, compared to the human cytomegalovirus promoter vIL-10 lentiviral-transduced cardiac allografts J Zhao et al (hCMV), it is associated with more sustained gene expression in cardiac grafts (data not shown). It has also been reported that the hCMV promoter can be downregulated by proinflammatory cytokines. 33 In this expression system, only the vector plasmid HIV-PGK-vIL-10 has the packaging signal (C), which enables its RNA to be packaged into virions and hence integrated into the target host cell DNA.
Vector production and transduction
Pseudotyped vectors were generated by transfection of plasmid DNA into 293T cells using a modified calcium phosphate method. 38 Transfections were carried out in 100 mm dishes using optimized ratios of constructs: 10 mg vector plasmid, 6.5 mg of the packaging plasmid, 2 mg of Rev expressor and 3.5 mg of the VSV-G env plasmid DNA per 10 ml of Dulbecco's modified Eagle's medium (DMEM) including 10% fetal calf serum (FCS) and 100 U/ml penicillin/streptomycin. The medium was changed 12-14 h later. At 62 h after the start of transfection, the medium was removed and filtered through a 0.45 mm Millex-HA filter (Millipore). Vectors were concentrated by ultracentrifugation for 90 min at 25 000 r.p.m. (41C) in a Beckman SW28 rotor centrifuge. Virion stocks were resuspended in phosphate-buffered saline (PBS) with 1% bovine serum albumin (BSA) and stored at À801C. Vectors were quantitated by comparison to GFP-expressing vectors. The GFP vectors were titred on SV2 cells by counting GFP-positive cells 72 h posttransduction. vIL-10 vectors were quantitated by using equivalent amounts as judged by p24 ELISA and described as containing equivalent TU/ml. The dose of vector administered was the highest concentration of vector that could be reproducibly obtained using this method and was estimated to be the equivalent of 10 7 TU/ml.
Animals
Inbred male Lewis rats (RT1 l ) and DA rats (RT1 av1 ) weighing 200-300 g, and outbred Sprague-Dawley rats were obtained from Charles River, UK. For allograft studies, Lewis donor hearts were transplanted to DA recipients. Rats were cared for by the University of Cambridge Central Biomedical Services and were housed in individually ventilated cages with sterilized food and water ad libitum. Regulated procedures were carried out strictly according to current UK law.
Isolation and culture of RAECs
Thoracic aortas were excised from DA rats and the surrounding fibroadipose tissue removed under a dissecting microscope. They were incised longitudinally, then washed twice with Hank's balanced salt solution (HBSS; Gibco, UK) and digested with 2 ml of 1 mg/ml collagenase (Worthington, UK) in a 371C incubator with 5% CO 2 . After 15 min incubation, the inner surface of the aorta was gently scraped with a scalpel and the released cells transferred into collagenase solution in a centrifuge tube. Samples were washed with HBSS, pooled and centrifuged for 10 min at 2000 r.p.m. (700 g). The cell pellet was resuspended in endothelial growth medium (CS-C medium (Sigma, UK), containing 20% FCS, 100 U/ ml penicillin/streptomycin, endothelial cell growth factor (Sigma, UK) and endothelial cell growth supplement (Sigma, UK)) and cells were cultured in six-well plates precoated with endothelial cell attachment factor (Sigma, UK) at 371C with 5% CO 2 until they reached confluence. The purity of endothelial cells was X90% as determined by morphology. For this study, cells from primary culture up to the third passage were used to avoid possible phenotypic changes during continuous culture.
Transduction of RAECs
RAECs were plated at 40-50% confluence 24 h prior to transduction in six-well plates. Medium was replaced immediately pretransduction with minimal quantities of covering medium and viral vector added at an m.o.i. of 0.5-1. Plates were incubated for a minimum of 6 h and 6 ml fresh medium added. Cells were left for 72 h before any further manipulations.
Isolation and culture of rat neonatal cardiomyocytes
Neonatal rat ventricular cardiac myocytes were prepared from 1-to 2-day-old Sprague-Dawley rats as described previously. 39 Briefly, cells from neonatal rat ventricles were dispersed in a series of incubations at 371C in HBSS containing 0.6 mg/ml pancreatin and 0.5 mg/ml collagenase. The dispersed cells were preplated for at least 30 min to minimize fibroblast contamination and the unattached cells replated on six-well gelatin-coated plates at a density of 2-5 Â 10 5 cells/well. The cardiac myocytes were cultured at 371C in 5% CO 2 in 4:1 DMEM:Medium 199 (M199), supplemented with 10% horse serum, 5% FCS and 100 U/ml penicillin/streptomycin for the first 24 h. Thereafter, cells were maintained in an identical medium with a reduced serum concentration of 1% FCS. Under these conditions, in excess of 90% of cells beat spontaneously for the duration of the experiment. Experiments were performed after 2-3 days in culture.
Heart transplantation model and vIL-10 gene transfer
Rat heterotopic abdominal heart transplantation was performed using standard microsurgical techniques. 40 Under general anaesthesia, a median sternotomy was performed in the donor to expose the heart. Heparin (500 U) was given i.v. and the donor heart was arrested with an infusion of cold saline and then excised. Donor hearts were transplanted heterotopically into recipients with end to side anastomosis of the aorta and the pulmonary artery to the abdominal aorta and inferior vena cava respectively using 9/0 monofilament sutures. The total period of ischaemia was approximately 30 min. Direct injection of HIV-PGK-vIL-10 or HIV-PGK-f was performed immediately after reperfusion of cardiac transplants and restoration of the heartbeat. A 200 ml (1 Â 10 6 TU) portion of viral vector was injected by slow infusion over 60 s using a 29-gauge needle. The needle was inserted to a depth of 3 mm, perpendicular to the long axis of the transplanted heart and approximately 2-3 mm from the apex, raising a visible bleb that gradually resolved. The quantity injected was limited by volume to avoid disruption of the cardiac muscle. Previous work had demonstrated that the coronary infusion route was extremely inefficient probably because of the inadequate time of vector/cell contact (not shown).
All rats received analgesia postoperatively and were recovered in a warm environment. Graft function was checked daily by palpation. Rejection was defined as vIL-10 lentiviral-transduced cardiac allografts J Zhao et al total cessation of cardiac contraction and confirmed by histological examination. A minimum of four rats per experimental condition were assessed. Additional transplants were performed to determine whether CsA administered at the time of transplantation in a single dose of 10 mg/kg by gavage would act synergistically with the vIL-10.
Heart excision, histochemical analysis and rejection grading At the termination of the experiment, transplanted hearts were removed and flushed with saline. The heart was embedded in OCT compound (Bright Instrument Company Ltd, UK), snap-frozen in liquid nitrogen and 10 mm cryostat sections were cut. Slides with sections cut at 50 mm intervals were fixed with cold acetone for 90 s. For assessment of rejection, the slides were stained with haematoxylin and eosin to evaluate the general morphology and grade of myocardial rejection. Rejection was scored according to the guidelines set by the Heart Rejection Working Group. 41 
Immunofluorescent staining
Cryostat sections were fixed in acetone at 41C for 90 s and rehydrated in Tris-buffered saline with 3% BSA to block nonspecific reactions. They were then incubated with primary monoclonal antibody to CD3 (Serotec, UK), CD4 (Serotec, UK) or CD8 (Serotec, UK) for T cells and CD14 (Sigma, UK) for macrophages. FITC-or PEconjugated secondary antibody labelling was detected using fluorescence microscopy.
RNA preparation and DNA amplification (RT-PCR)
Total RNA from cardiac allografts and other organs was isolated from frozen tissue using a commercial RNAeasy protection kit (Promega, UK). The final RNA pellet was resuspended in RNase-free water. The quality of RNA was verified by denaturing RNA gels. The mRNA of each sample was analysed by reverse transcription and subsequent polymerase chain reaction (RT-PCR). A 500 ng portion of total RNA was used. The vIL-10 primer sequences were: sense, 5 0 -ATGGAGCGAAGGTTAGT GGTC; antisense, 5 0 -ACTCTTGTTCTCACACGGCAG, yielding a 388-basepair product.
A total of 30 cycles of PCR were performed (941C for 1 min, 561C for 1 min, 721C for 1 min) with a final extension of 721C for 5 min and then maintained at 41C. Amplified PCR products were analysed by electrophoresis on 1% agarose gels. To confirm that detection of mRNA expression was not due to the DNA from infused HIV-PGK-vIL-10 vectors, the same samples were submitted for the PCR without the RT step. PCR amplification of the rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) housekeeping gene was performed to assess variations in cDNA or total RNA loading among samples. The primer sequences for rat GAPDH were: sense, 5 0 -TCCACCACCCTGTTGCTGATG; antisense, 5 0 -GACCACAGTCCATGACATCACT, yielding a 452-basepair product.
vIL-10 ELISA assay vIL-10 production in supernatants of transduced RAECs and neonatal cardiomyocytes, and serum vIL-10 from tail vein blood were measured on the indicated days after gene transfer with a commercial ELISA kit specific for vIL-10 (Biosource International, UK).
Lymphocyte proliferation assay
Lymphocyte proliferation assays were performed essentially as described previously. 35 Irradiated DA lymph node cells, comprising approximately 77% T lymphocytes, 23 were used as stimulators (4 Â 10 5 /well). MLRs were cultured for 5 days in round-bottom 96-well plates at 371C in 5% CO 2 using RPMI 1640 medium (Gibco-BRL) supplemented with 10% FCS, 2 mM L-glutamine (Gibco-BRL), 100 mg/ml streptomycin, 100 U/ml penicillin, 2 mg/ml gentamicin (Gibco-BRL) and 50 mM 2-mercaptoethanol. Con A (5 mg/ml)-stimulated lymphocyte proliferation was for 4 days. Culture supernatant containing bioactive vIL-10, produced by transducing DA RAECs with HIV-PGK-vIL-10, was tested and added, at different time points, to the MLRs. Viral vector HIV-PGK-GFP was used as control. Proliferation was assessed by uptake of [ 3 H]thymidine for 6 h at the end of the culture period.
Statistical analysis
Values are expressed as mean7s.e. or, for transplant studies, MST. Within each independent in vitro experiment, at least duplicate measurements were performed. The values from each in vitro experiment were pooled to allow statistical comparisons, performed using a singlefactor analysis of variance with Newman-Keuls post-test for pair comparisons (GraphPad Prism). Graft survival data were compared using the Mann-Whitney U-test. A probability value Po0.05 was considered significant.
